The mechanistic basis for the induction of hepatic steatosis by xenobiotics

Bibliography

• Zimmerman HJ. Hepatoxicity. The adverse effects of drugs and other chemicals on the liver. Lippincott Williams & Wilkins, Philadelphia; 1999. p. 61
   Google Scholar
• Fromenty B, Pessayre D. Impaired mitochondrial function in microvesicular steatosis. Effects of drugs, ethanol, hormones and cytokines. J Hepatol 1997;26(Suppl 2):43-53
   PubMed Web of Science ®Google Scholar
• Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis 2010;9:42
   PubMed Web of Science ®Google Scholar
• Guzman M, Castro J. Zonation of fatty acid metabolism in rat liver. Biochem J 1989;264:107-13
   PubMed Web of Science ®Google Scholar
• Tong L. Acetyl-coenzyme A carboxylase: crucial metabolic enzyme and attractive target for drug discovery. Cell Mol Life Sci 2005;62:1784-803
   PubMed Web of Science ®Google Scholar
• Wang D, Sul HS. Insulin stimulation of the fatty acid synthase promoter is mediated by the phosphatidylinositol 3-kinase pathway. Involvement of protein kinase B/Akt. J Biol Chem 1998;273:25420-6
   PubMed Web of Science ®Google Scholar
• Mauvoisin D, Mounier C. Hormonal and nutritional regulation of SCD1 gene expression. Biochimie 2011;93:78-86
   PubMed Web of Science ®Google Scholar
• Vallim T, Salter AM. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2010;82(4-6):211-18
   PubMed Web of Science ®Google Scholar
• Harada N, Oda Z, Hara Y, Hepatic de novo lipogenesis is present in liver-specific ACC1-deficient mice. Mol Cell Biol 2007;27:1881-8
   PubMed Web of Science ®Google Scholar
• Abu-Elheiga L, Brinkley WR, Zhong L, The subcellular localization of acetyl-CoA carboxylase 2. Proc Natl Acad Sci USA 2000;97:1444-9
   PubMed Web of Science ®Google Scholar
• Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52
   PubMed Web of Science ®Google Scholar
• Bayascas JR. Dissecting the role of the 3-phosphoinositide-dependent protein kinase-1 (PDK1) signalling pathways. Cell Cycle 2008;7:2978-82
   PubMed Web of Science ®Google Scholar
• Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 2010;2:589-98
   Google Scholar
• Cheng Z, White MF. Targeting Forkhead box O1 from the concept to metabolic diseases: lessons from mouse models. Antioxid Redox Signal 2011;14:649-61
   PubMed Web of Science ®Google Scholar
• Kamagate A, Dong HH. FoxO1 integrates insulin signaling to VLDL production. Cell Cycle 2008;7:3162-70
   PubMed Web of Science ®Google Scholar
• Porstmann T, Griffiths B, Chung YL, PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 2005;24:6465-81
   PubMed Web of Science ®Google Scholar
• Denechaud PD, Girard J, Postic C. Carbohydrate responsive element binding protein and lipid homeostasis. Curr Opin Lipidol 2008;19:301-6
   PubMed Web of Science ®Google Scholar
• Baranowski M. Biological role of liver X receptors. J Physiol Pharmacol 2008;59(Suppl 7):31-55
   PubMedGoogle Scholar
• Iizuka K, Horikawa Y. ChREBP: a glucose-activated transcription factor involved in the development of metabolic syndrome. Endocr J 2008;55:617-24
   PubMed Web of Science ®Google Scholar
• Rawson RB. Control of lipid metabolism by regulated intramembrane proteolysis of sterol regulatory element binding proteins (SREBPs). Biochem Soc Symp 2003;70:221-31
   PubMed Web of Science ®Google Scholar
• Yang T, Espenshade PJ, Wright ME, Crucial step in cholesterol homeostasis: sterols promote binding of SCAP to INSIG-1, a membrane protein that facilitates retention of SREBPs in ER. Cell 2002;110:489-500
   PubMed Web of Science ®Google Scholar
• Feramisco JD, Goldstein JL, Brown MS. Membrane topology of human insig-1, a protein regulator of lipid synthesis. J Biol Chem 2004;279:8487-96
   PubMed Web of Science ®Google Scholar
• Konig B, Koch A, Spielmann J, Activation of PPARalpha and PPARgamma reduces triacylglycerol synthesis in rat hepatoma cells by reduction of nuclear SREBP-1. Eur J Pharmacol 2009;605:23-30
   PubMed Web of Science ®Google Scholar
• Villanueva CJ, Monetti M, Shih M, Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 2009;50:434-42
   PubMed Web of Science ®Google Scholar
• Ringseis R, Muschick A, Eder K. Dietary oxidized fat prevents ethanol-induced triacylglycerol accumulation and increases expression of PPARalpha target genes in rat liver. J Nutr 2007;137:77-83
   PubMed Web of Science ®Google Scholar
• You M, Liang X, Ajmo JM, Ness GC. Involvement of mammalian sirtuin 1 in the action of ethanol in the liver. Am J Physiol Gastrointest Liver Physiol 2008;294:G892-8
   PubMed Web of Science ®Google Scholar
• You M, Rogers CQ. Adiponectin: a key adipokine in alcoholic fatty liver. Exp Biol Med (Maywood) 2009;234:850-9
   PubMed Web of Science ®Google Scholar
• Shen Z, Liang X, Rogers CQ, Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol Gastrointest Liver Physiol 2010;298:G364-74
   PubMed Web of Science ®Google Scholar
• Ge F, Zhou S, Hu C, Insulin- and leptin-regulated fatty acid uptake plays a key causal role in hepatic steatosis in mice with intact leptin signaling but not in ob/ob or db/db mice. Am J Physiol Gastrointest Liver Physiol 2010;299:G855-66
   PubMed Web of Science ®Google Scholar
• Nishino M, Hayakawa K, Nakamura Y, Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am J Roentgenol 2003;180:129-34
   PubMed Web of Science ®Google Scholar
• Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010;52:1258-65
   PubMed Web of Science ®Google Scholar
• Wang YM, Hu XQ, Xue Y, Study on possible mechanism of orotic acid-induced fatty liver in rats. Nutrition 2010; published online 16 December 2010 doi:10.1016/j.nut.2010.03.005
   Web of Science ®Google Scholar
• Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr 1996;16:523-57
   PubMed Web of Science ®Google Scholar
• Diraison F, Beylot M. Role of human liver lipogenesis and reesterification in triglycerides secretion and in FFA reesterification. Am J Physiol 1998;274(2 Pt 1):E321-7
   PubMed Web of Science ®Google Scholar
• Foster DW. The role of the carnitine system in human metabolism. Ann NY Acad Sci 2004;1033:1-16
   PubMed Web of Science ®Google Scholar
• Bonnefont JP, Djouadi F, Prip-Buus C, Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med 2004;25:495-520
   PubMedGoogle Scholar
• Song S, Attia RR, Connaughton S, Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol 2010;325:54-63
   PubMed Web of Science ®Google Scholar
• van der Leij FR, Bloks VW, Grefhorst A, Gene expression profiling in livers of mice after acute inhibition of beta-oxidation. Genomics 2007;90:680-9
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Saha AK, Kraegen EW. Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 2003;144:5166-71
   PubMed Web of Science ®Google Scholar
• Ruderman NB, Park H, Kaushik VK, AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand 2003;178:435-42
   PubMedGoogle Scholar
• Canto C, Gerhart-Hines Z, Feige JN, AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009;458:1056-60
   PubMed Web of Science ®Google Scholar
• Whitehead JP, Richards AA, Hickman IJ, Adiponectin–a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006;8:264-80
   PubMed Web of Science ®Google Scholar
• Chaudhary N, Pfluger PT. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009;12:431-7
   PubMed Web of Science ®Google Scholar
• Rodgers JT, Lerin C, Haas W, Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005;434:113-18
   PubMed Web of Science ®Google Scholar
• Spiegelman BM. Transcriptional control of mitochondrial energy metabolism through the PGC1 coactivators. Novartis Found Symp 2007;287:60-3
   PubMedGoogle Scholar
• Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000;20:1868-76
   PubMed Web of Science ®Google Scholar
• Estall JL, Kahn M, Cooper MP, Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 2009;58:1499-508
   PubMed Web of Science ®Google Scholar
• Lomb DJ, Laurent G, Haigis MC. Sirtuins regulate key aspects of lipid metabolism. Biochim Biophys Acta 2010;1804:1652-7
   PubMed Web of Science ®Google Scholar
• Killalea SM, Krum H. Systematic review of the efficacy and safety of perhexiline in the treatment of ischemic heart disease. Am J Cardiovasc Drugs 2001;1:193-204
   PubMedGoogle Scholar
• Ashrafian H, Horowitz JD, Frenneaux MP. Perhexiline. Cardiovasc Drug Rev 2007;25:76-97
   PubMed Web of Science ®Google Scholar
• Deschamps D, DeBeco V, Fisch C, Inhibition by perhexiline of oxidative phosphorylation and the beta-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology 1994;19:948-61
   PubMed Web of Science ®Google Scholar
• Fromenty B, Fisch C, Labbe G, Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990;255:1371-6
   PubMed Web of Science ®Google Scholar
• Lewis JH, Mullick F, Ishak KG, Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990;21:59-67
   PubMed Web of Science ®Google Scholar
• Kennedy JA, Unger SA, Horowitz JD. Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 1996;52:273-80
   PubMed Web of Science ®Google Scholar
• McCarthy TC, Pollak PT, Hanniman EA, Sinal CJ. Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. J Pharmacol Exp Ther 2004;311:864-73
   PubMed Web of Science ®Google Scholar
• Freneaux E, Labbe G, Letteron P, Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology 1988;8:1056-62
   PubMed Web of Science ®Google Scholar
• Le Dinh T, Freneaux E, Labbe G, Amineptine, a tricyclic antidepressant, inhibits the mitochondrial oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1988;247:745-50
   PubMed Web of Science ®Google Scholar
• Geneve J, Hayat-Bonan B, Labbe G, Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this nonsteroidal anti-inflammatory drug. J Pharmacol Exp Ther 1987;242:1133-7
   PubMed Web of Science ®Google Scholar
• Fromenty B, Freneaux E, Labbe G, Tianeptine, a new tricyclic antidepressant metabolized by beta-oxidation of its heptanoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem Pharmacol 1989;38:3743-51
   PubMed Web of Science ®Google Scholar
• Silva MF, Aires CC, Luis PB, Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008;31:205-16
   PubMed Web of Science ®Google Scholar
• Natarajan SK, Eapen CE, Pullimood AB, Balasubramanian KA. Oxidative stress in experimental liver microvesicular steatosis: role of mitochondria and peroxisomes. J Gastroenterol Hepatol 2006;21:1240-9
   PubMed Web of Science ®Google Scholar
• Jolly RA, Ciurlionis R, Morfitt D, Microvesicular steatosis induced by a short chain fatty acid: effects on mitochondrial function and correlation with gene expression. Toxicol Pathol 2004;32(Suppl 2):19-25
   PubMedGoogle Scholar
• Berson A, De Beco V, Letteron P, Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998;114:764-74
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Gaffey MJ, Sallie R, Histopathologic changes associated with fialuridine hepatotoxicity. Mod Pathol 1997;10:192-9
   PubMed Web of Science ®Google Scholar
• Lai Y, Tse CM, Unadkat JD. Mitochondrial expression of the human equilibrative nucleoside transporter 1 (hENT1) results in enhanced mitochondrial toxicity of antiviral drugs. J Biol Chem 2004;279:4490-7
   PubMed Web of Science ®Google Scholar
• Lee EW, Lai Y, Zhang H, Unadkat JD. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. J Biol Chem 2006;281:16700-6
   PubMed Web of Science ®Google Scholar
• Hussain MM, Bakillah A. New approaches to target microsomal triglyceride transfer protein. Curr Opin Lipidol 2008;19:572-8
   PubMed Web of Science ®Google Scholar
• Puljak L, Parameswara V, Dolovcak S, Evidence for AMPK-dependent regulation of exocytosis of lipoproteins in a model liver cell line. Exp Cell Res 2008;314:2100-9
   PubMed Web of Science ®Google Scholar
• Letteron P, Sutton A, Mansouri A, Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology 2003;38:133-40
   PubMed Web of Science ®Google Scholar
• Deboyser D, Goethals F, Krack G, Roberfroid M. Investigation into the mechanism of tetracycline-induced steatosis: study in isolated hepatocytes. Toxicol Appl Pharmacol 1989;97:473-9
   PubMed Web of Science ®Google Scholar
• Lopez-Parra M, Titos E, Horrillo R, Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res 2008;49:2513-23
   PubMed Web of Science ®Google Scholar
• Horrillo R, Gonzalez-Periz A, Martinez-Clemente M, 5-lipoxygenase activating protein signals adipose tissue inflammation and lipid dysfunction in experimental obesity. J Immunol 2010;184:3978-87
   Google Scholar
• Sugimoto T, Yamashita S, Ishigami M, Decreased microsomal triglyceride transfer protein activity contributes to initiation of alcoholic liver steatosis in rats. J Hepatol 2002;36:157-62
   PubMed Web of Science ®Google Scholar
• Nossen JO, Rustan AC, Drevon CA. Calcium-antagonists inhibit secretion of very-low-density lipoprotein from cultured rat hepatocytes. Biochem J 1987;247:433-9
   PubMed Web of Science ®Google Scholar
• Pan X, Hussain FN, Iqbal J, Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCl4-induced steatosis. J Biol Chem 2007;282:17078-89
   PubMed Web of Science ®Google Scholar
• Boll M, Weber LW, Becker E, Stampfl A. Hepatocyte damage induced by carbon tetrachloride: inhibited lipoprotein secretion and changed lipoprotein composition. Z Naturforsch C 2001;56:283-90
   PubMed Web of Science ®Google Scholar
• Weber LW, Boll M, Stampfl A. Hepatotoxicity and mechanism of action of haloalkanes: carbon tetrachloride as a toxicological model. Crit Rev Toxicol 2003;33:105-36
   PubMed Web of Science ®Google Scholar
• Larosche I, Letteron P, Fromenty B, Tamoxifen inhibits topoisomerases, depletes mitochondrial DNA, and triggers steatosis in mouse liver. J Pharmacol Exp Ther 2007;321:526-35
   PubMed Web of Science ®Google Scholar
• Luiken JJ, Bonen A, Glatz JF. Cellular fatty acid uptake is acutely regulated by membrane-associated fatty acid-binding proteins. Prostaglandins Leukot Essent Fatty Acids 2002;67:73-8
   PubMed Web of Science ®Google Scholar
• Stremmel W, Pohl L, Ring A, Herrmann T. A new concept of cellular uptake and intracellular trafficking of long-chain fatty acids. Lipids 2001;36:981-9
   PubMed Web of Science ®Google Scholar
• van Oort MM, van Doorn JM, Hasnaoui ME, Effects of AMPK activators on the sub-cellular distribution of fatty acid transporters CD36 and FABPpm. Arch Physiol Biochem 2009;115:137-46
   PubMedGoogle Scholar
• Zhou J, Febbraio M, Wada T, Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008;134:556-67
   PubMed Web of Science ®Google Scholar
• Donnelly KL, Smith CI, Schwarzenberg SJ, Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-51
   PubMed Web of Science ®Google Scholar
• Zhu L, Baker SS, Liu W, Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism 2010: published online 15 November 2010, DOI: 10.1016/j.metabol.2010.10.003
   Web of Science ®Google Scholar
• Greco D, Kotronen A, Westerbacka J, Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008;294:G1281-7
   PubMed Web of Science ®Google Scholar
• Mattson MP, LaFerla FM, Chan SL, Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2000;23:222-9
   PubMed Web of Science ®Google Scholar
• Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 2005;115:2656-64
   PubMed Web of Science ®Google Scholar
• Rao RV, Castro-Obregon S, Frankowski H, Coupling endoplasmic reticulum stress to the cell death program. An Apaf-1-independent intrinsic pathway. J Biol Chem 2002;277:21836-42
   PubMed Web of Science ®Google Scholar
• Flamment M, Kammoun HL, Hainault I, Endoplasmic reticulum stress: a new actor in the development of hepatic steatosis. Curr Opin Lipidol 2010;21:239-46
   PubMed Web of Science ®Google Scholar
• Ota T, Gayet C, Ginsberg HN. Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest 2008;118:316-32
   PubMed Web of Science ®Google Scholar
• Kammoun HL, Hainault I, Ferre P, Foufelle F. Nutritional related liver disease: targeting the endoplasmic reticulum stress. Curr Opin Clin Nutr Metab Care 2009;12:575-82
   PubMed Web of Science ®Google Scholar
• Rahman SM, Qadri I, Janssen RC, Friedman JE. Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis. J Lipid Res 2009;50:2193-202
   PubMed Web of Science ®Google Scholar
• Malhi H, Kaufman RJ. Endoplasmic reticulum stress in liver disease. J Hepatol 2010: published online 09 December 2010, DOI: 10.1016/j.jhep.2010.11.005
   PubMed Web of Science ®Google Scholar
• Lee AH, Scapa EF, Cohen DE, Glimcher LH. Regulation of hepatic lipogenesis by the transcription factor XBP1. Science 2008;320:1492-6
   PubMed Web of Science ®Google Scholar
• Glimcher LH, Lee AH. From sugar to fat: How the transcription factor XBP1 regulates hepatic lipogenesis. Ann NY Acad Sci 2009;1173(Suppl 1):E2-9
   PubMedGoogle Scholar
• Ni M, Lee AS. ER chaperones in mammalian development and human diseases. FEBS Lett 2007;581:3641-51
   PubMed Web of Science ®Google Scholar
• Lee AH, Glimcher LH. Intersection of the unfolded protein response and hepatic lipid metabolism. Cell Mol Life Sci 2009;66:2835-50
   PubMed Web of Science ®Google Scholar
• Schroeder-Gloeckler JM, Rahman SM, Janssen RC, CCAAT/enhancer-binding protein beta deletion reduces adiposity, hepatic steatosis, and diabetes in Lepr(db/db) mice. J Biol Chem 2007;282:15717-29
   PubMed Web of Science ®Google Scholar
• Pfaffenbach KT, Nivala AM, Reese L, Rapamycin inhibits postprandial-mediated X-box-binding protein-1 splicing in rat liver. J Nutr 2010;140:879-84
   PubMed Web of Science ®Google Scholar
• Rutkowski DT, Wu J, Back SH, UPR pathways combine to prevent hepatic steatosis caused by ER stress-mediated suppression of transcriptional master regulators. Dev Cell 2008;15:829-40
   PubMed Web of Science ®Google Scholar
• Sugden MC, Caton PW, Holness MJ. PPAR control: it's SIRTainly as easy as PGC. J Endocrinol 2010;204:93-104
   PubMed Web of Science ®Google Scholar
• Moya M, Gomez-Lechon MJ, Castell JV, Jover R. Enhanced steatosis by nuclear receptor ligands: a study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile. Chem Biol Interact 2010;184:376-87
   PubMed Web of Science ®Google Scholar
• Su X, Abumrad NA. Cellular fatty acid uptake: a pathway under construction. Trends Endocrinol Metab 2009;20:72-7
   PubMed Web of Science ®Google Scholar
• Wolf G. Endogenous ligand for an orphan receptor. Nutr Rev 2010;68:316-18
   PubMed Web of Science ®Google Scholar
• Gao J, He J, Zhai Y, The constitutive androstane receptor is an anti-obesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009;284:25984-92
   PubMed Web of Science ®Google Scholar
• Oosterveer MH, Grefhorst A, Groen AK, Kuipers F. The liver X receptor: control of cellular lipid homeostasis and beyond Implications for drug design. Prog Lipid Res 2010;49:343-52
   PubMed Web of Science ®Google Scholar
• Ide T, Shimano H, Yoshikawa T, Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol Endocrinol 2003;17:1255-67
   PubMed Web of Science ®Google Scholar
• Cha JY, Repa JJ. The liver X receptor (LXR) and hepatic lipogenesis. The carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem 2007;282:743-51
   PubMed Web of Science ®Google Scholar
• Wojcicka G, Jamroz-Wisniewska A, Horoszewicz K, Bełtowski J. Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. Postepy Hig Med Dosw (Online) 2007;61:736-59
   PubMedGoogle Scholar
• Peng D, Hiipakka RA, Xie JT, A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR-/- mice. Br J Pharmacol 2011; Accepted Article; doi: 10.1111/j.1476-5381.2011.01202.x
   Web of Science ®Google Scholar
• Grefhorst A, Elzinga BM, Voshol PJ, Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 2002;277:34182-90
   PubMed Web of Science ®Google Scholar
• Mitro N, Vargas L, Romeo R, T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett 2007;58:1721-6
   Google Scholar
• Wierzbicki M, Chabowski A, Zendzian-Piotrowska M, Gorski J. Differential effects of in vivo PPAR alpha and gamma activation on fatty acid transport proteins expression and lipid content in rat liver. J Physiol Pharmacol 2009;60:99-106
   PubMed Web of Science ®Google Scholar
• Kawano Y, Nishiumi S, Tanaka S, Activation of the aryl hydrocarbon receptor induces hepatic steatosis via the upregulation of fatty acid transport. Arch Biochem Biophys 2010;504:221-7
   PubMed Web of Science ®Google Scholar
• Huang J, Iqbal J, Saha PK, Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 2007;46:147-57
   PubMed Web of Science ®Google Scholar
• Lee JH, Zhou J, Xie W. PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol Pharm 2008;5:60-6
   PubMed Web of Science ®Google Scholar
• Yin HQ, Kim M, Kim JH, Hepatic gene expression profiling and lipid homeostasis in mice exposed to steatogenic drug, tetracycline. Toxicol Sci 2006;94:206-16
   PubMed Web of Science ®Google Scholar
• Lee MH, Hong I, Kim M, Gene expression profiles of murine fatty liver induced by the administration of methotrexate. Toxicology 2008;249:75-84
   PubMed Web of Science ®Google Scholar
• Lee MH, Hong I, Kim M, Gene expression profiles of murine fatty liver induced by the administration of valproic acid. Toxicol Appl Pharmacol 2007;220:45-59
   PubMed Web of Science ®Google Scholar
• Lelliott CJ, Lopez M, Curtis RK, Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J 2005;19:1108-19
   PubMed Web of Science ®Google Scholar
• Amacher DE. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology 2011;279:10-18
   PubMed Web of Science ®Google Scholar
• Amacher DE, Martin BA. Tetracycline-induced steatosis in primary canine hepatocyte cultures. Fundam Appl Toxicol 1997;40:256-63
   PubMedGoogle Scholar
• McMillian MK, Grant ER, Zhong Z, Nile Red binding to HepG2 cells: an improved assay for in vitro studies of hepatosteatosis. In Vitr Mol Toxicol 2001;14:177-90
   PubMedGoogle Scholar
• Donato MT, Martinez-Romero A, Jimenez N, Cytometric analysis for drug-induced steatosis in HepG2 cells. Chem Biol Interact 2009;181:417-23
   PubMed Web of Science ®Google Scholar
• Fujimura H, Murakami N, Kurabe M, Toriumi W. In vitro assay for drug-induced hepatosteatosis using rat primary hepatocytes, a fluorescent lipid analog and gene expression analysis. J Appl Toxicol 2009;29:356-63
   PubMed Web of Science ®Google Scholar
• Pessayre D, Larrey D. Acute and chronic drug-induced hepatitis. Baillieres Clin Gastroenterol 1988;2:385-422
   PubMedGoogle Scholar
• Viollet B, Athea Y, Mounier R, AMPK: Lessons from transgenic and knockout animals. Front Biosci 2009;14:19-44
   PubMed Web of Science ®Google Scholar
• Akkaoui M, Cohen I, Esnous C, Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids. Biochem J 2009;420:429-38
   PubMed Web of Science ®Google Scholar
• Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta 2000;1486(1):17
   PubMed Web of Science ®Google Scholar
• Baur JA. Biochemical effects of SIRT1 activators. Biochim Biophys Acta 2010;1804:1626-34
   PubMed Web of Science ®Google Scholar
• Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002;109:1125-31
   PubMed Web of Science ®Google Scholar
• Krycer JR, Sharpe LJ, Luu W, Brown AJ. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol Metab 2010;21:268-76
   PubMed Web of Science ®Google Scholar
• Eberle D, Hegarty B, Bossard P, SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004;86:839-48
   PubMed Web of Science ®Google Scholar